Division of Medical Therapeutics for Heart Failure

Our division was born in January, 2015 as a new research group of Department of Cardiovascular Medicine in Osaka University Graduate School of Medicine. Our goal is to develop a novel diagnostic tool or medical therapy for intractable cardiovascular diseases including advanced heart failure, using bidirectional approaches both from clinical information, clinical samples and from latest molecular biology techniques.

Research Aim

Development of medical therapy for intractable cardiovascular diseases, especially targeting advanced heart failure (idiopathic cardiomyopathy, storage disease, mitochondrial disease) which is refractory to standard pharmacological and non-pharmacological therapy.

Research Content

  • Therepeutic application of CRISPR/Cas9 genome editing technologies into cardiovascular medicine.
  • Development of diagnostic and therapeutic method using patient-derived iPC cells.
  • Molecular discovery research through non-biased screening tool using high-throughput sequencer (RNA-sequence, ChIP-sequence) and original analytical pipelines.
  • Elucidation of novel mechanisms of heart failure, especially focused on mitochondrial biology, fibrosis and DNA damage response.